Type I IFN receptor blockade by anifrolumab reduces cutaneous lupus in monogenic SLE

This publication has 12 references indexed in Scilit:

• Hereditary C1q Deficiency is Associated with Type 1 Interferon-Pathway Activation and a High Risk of Central Nervous System Inflammation
  Journal of Clinical Immunology, 2024
• Anifrolumab for the treatment of refractory chilblain lupus erythematosus
  JAAD Case Reports, 2023
• Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus
  JAMA Dermatology, 2023
• Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers
  British Journal of Dermatology, 2023
• Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus
  Journal of the American Academy of Dermatology, 2023
• The complement system and human autoimmune diseases
  Journal of Autoimmunity, 2022
• Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
  Annals of the Rheumatic Diseases, 2022
• Janus kinase inhibition in complement component 1 deficiency
  Journal of Allergy and Clinical Immunology, 2020
• Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review
  Drugs, 2019
• The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus
  Journal of Investigative Dermatology, 2005